首页 | 本学科首页   官方微博 | 高级检索  
     


Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised,open-label,multicentre, non-inferiority,phase 3 study
Authors:Antoinette R Tan  Seock-Ah Im  André Mattar  Ramon Colomer  Daniil Stroyakovskii  Zbigniew Nowecki  Michelino De Laurentiis  Jean-Yves Pierga  Kyung Hae Jung  Christian Schem  Alexandra Hogea  Tanja Badovinac Crnjevic  Sarah Heeson  Mahesh Shivhare  Whitney P Kirschbrown  Eleonora Restuccia  Christian Jackisch
Affiliation:1. Levine Cancer Institute, Atrium Health, Charlotte, NC, USA;2. Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea;3. Hospital Pérola Byington, São Paulo, Brazil;4. Hospital Universitario La Princesa, Madrid, Spain;5. City Clinical Oncology Hospital 62, Moscow, Russia;6. Centrum Onkologii-Instytut, Warsaw, Poland;7. Istituto Nazionale Tumori IRCCS ‘Fondazione Pascale’, Napoli, Italy;8. Institut Curie and Université de Paris, Paris, France;9. Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;10. Mammazentrum Hamburg, Hamburg, Germany;11. Roche Products, Welwyn Garden City, UK;12. F Hoffmann-La Roche, Basel, Switzerland;13. Genentech, South San Francisco, CA, USA;14. Sana Klinikum Offenbach, Offenbach, Germany
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号